Immuron Ltd (IMRN) Form 6-K — Oct 28, 2026
Immuron Limited furnished a 6-K containing CEO Steven Lydeamore's presentation for the October 28, 2026 Emerging Growth Conference, outlining the company's strategic reset toward profitability and a partnering strategy for its clinical assets. The presentation reported FY26 global sales revenue of A$7.7 million, up 6% year over year, with a net loss of A$3.8 million (a A$1.4 million improvement) and cash of A$9.0 million at 30 June 2026 — enough to fund operations through FY27-FY28. Q1 FY27 global revenue was A$2.2 million, up 9%, driven by Australia (+14%) and Canada (+286%), though North America declined 9% on lower U.S. sales.
Key figures
- Revenue
- A$7.7m (FY26 global sales revenue)
- Net Income
- -A$3.8m (FY26 net profit, a A$1.4m improvement)
- Revenue Yoy
- +6% FY26; +9% Q1 FY27
- Cash Position
- A$9.0m @ 30 June 2026
- Runway
- 24 months; cash funds operations through FY27-FY28
- Market cap
- A$12.91m (26 October 2026)
- Us sales fy26
- A$1.8m (+7%, +13% in USD)
- Shares on issue
- 322848081
- Gross margin fy26
- 64.5%
- Q1 fy27 australia
- A$1.8m (+14%)
- Imrn 52wk high low
- $2.2099/0.6765
- Australian sales fy26
- A$5.8m (+10%)
- Q1 fy27 north america
- A$0.4m (-9%)
- Q1 fy27 global revenue
- A$2.2m (+9%)
- Imm529 peak us sales estimate
- US$400m (Lumanity)
- Imm124e peak us sales estimate
- US$102m (Lumanity)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.